Eric Coldwell
Stock Analyst at Baird
(3.62)
# 773
Out of 5,170 analysts
166
Total ratings
57.55%
Success rate
3.03%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Outperform | $19 → $16 | $9.81 | +63.18% | 10 | Feb 27, 2026 | |
| LH Labcorp Holdings | Maintains: Outperform | $313 → $326 | $264.09 | +23.44% | 15 | Feb 18, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $43.59 | +10.12% | 1 | Jan 12, 2026 | |
| MCK McKesson | Maintains: Outperform | $873 → $927 | $898.95 | +3.12% | 18 | Nov 6, 2025 | |
| CRL Charles River Laboratories International | Upgrades: Outperform | $178 → $199 | $153.05 | +30.02% | 15 | Nov 6, 2025 | |
| IQV IQVIA Holdings | Upgrades: Outperform | $224 → $258 | $166.47 | +54.98% | 19 | Oct 29, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $98.05 | +128.45% | 22 | Sep 2, 2025 | |
| DGX Quest Diagnostics | Downgrades: Neutral | $194 | $194.16 | -0.08% | 11 | Aug 25, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $210.92 | -3.75% | 13 | Aug 13, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $313 → $490 | $460.92 | +6.31% | 19 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $10.08 | +58.73% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $50.31 | -10.55% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $71.86 | -8.15% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $0.77 | +5,874.80% | 4 | Nov 10, 2017 |
Fortrea Holdings
Feb 27, 2026
Maintains: Outperform
Price Target: $19 → $16
Current: $9.81
Upside: +63.18%
Labcorp Holdings
Feb 18, 2026
Maintains: Outperform
Price Target: $313 → $326
Current: $264.09
Upside: +23.44%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $43.59
Upside: +10.12%
McKesson
Nov 6, 2025
Maintains: Outperform
Price Target: $873 → $927
Current: $898.95
Upside: +3.12%
Charles River Laboratories International
Nov 6, 2025
Upgrades: Outperform
Price Target: $178 → $199
Current: $153.05
Upside: +30.02%
IQVIA Holdings
Oct 29, 2025
Upgrades: Outperform
Price Target: $224 → $258
Current: $166.47
Upside: +54.98%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $98.05
Upside: +128.45%
Quest Diagnostics
Aug 25, 2025
Downgrades: Neutral
Price Target: $194
Current: $194.16
Upside: -0.08%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $210.92
Upside: -3.75%
Medpace Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $313 → $490
Current: $460.92
Upside: +6.31%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $10.08
Upside: +58.73%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $50.31
Upside: -10.55%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $71.86
Upside: -8.15%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $0.77
Upside: +5,874.80%